Objective. Lumbar intervertebral disk herniation (LDH) is considered one of the major risk factors for lower back pain, mainly caused by irritation of a spinal nerve or its root. One of the genes related to pain perception is SCN9A, which encodes the voltage gated sodium channel NaV1.7, a key molecule involved in peripheral pain processing. It had been presented before that a common polymorphism within SCN9A (rs6746030: G > A, R1150W) might influence nociception in the general population. Hence, the present study was aimed at investigating the association between SCN9A polymorphism and pain sensitivity.
Introduction
Lower back pain (LBP) is one of the most common musculoskeletal ailments and a major cause for disability, especially in high-income countries. Approximately 5-10% of patients develop chronic lower back pain that lasts longer than three months [1] . There are many different causes for lower back pain, and lumbar intervertebral disk degeneration and herniation (LDH) is considered one of the major risk factors. However, some subjects with LDH do not suffer from chronic pain, and some LPB patients do not show disc degeneration, evaluated by means of magnetic resonance imaging [2, 3] . LDH has possible anatomic and molecular mechanisms, related to a cascade of cellular, biochemical, structural and functional changes developing within the disc and surrounding tissues. Patients who suffer from LBP experience both nociceptive and neuropathic pain; thus discrimination of mechanisms triggering particular types of pain is challenging [4] .
The most common type of neuropathic pain in the course of degenerative disk disease is the radicular type, caused by irritation of a spinal nerve or its root due to inflammation, decreased blood supply of root ganglion, or its compression, which initiates and then propogates several distinct cellular and molecular mechanisms involving ion channels, cytokines, and neuropeptides [5] . The magnitude of the degeneration is strongly correlated with pain intensity. However, there is some scientific evidence that indicates an individual genetic predisposition to processing of sensory information, such as pain perception following noxious stimulation, development of pain, and efficacy of analgesics [6] .
One of the genes related to pain perception is SCN9A, which encodes an a-subunit of the voltage gated sodium channel NaV1.7, highly expressed in nociceptive neurons and recognized as a key molecule involved in peripheral pain processing [7] . Rare mutations in SCN9A, severely altering NaV1.7 function, were identified as a causative factor for different human genetic pain disorders. Unlike gain-of-function mutations, causing primary erythromelalgia and paroxysmal extreme pain disorder, nonsense mutations produce complete loss of NaV1.7 function, which results in channelopathyassociated insensitivity to pain [8] . Although subjects with major pain phenotypes are very rare, it has been presented that a common missense polymorphism within SCN9A gene (rs6746030: G > A; R1150W) might influence nociception in the general population, and the minor A allele was associated with increased pain scores [9] . Moreover, the latter authors presented that a single amino acid substitution caused by the studied SNP might alter the voltage-dependent slow inactivation of the NaV1.7 channel. The authors demonstrated that the rs6746030 A allele was associated with the increased activity of the NaV1.7 channel, leading to a lower pain threshold in minor allele carriers [9] .
So far, no clear relationship between pain intensity in patients with LDH and genetic variants in sodium channel functions has been found. Hence, the present study was aimed at investigating the association between the SCN9A gene (rs6746030: G > A) polymorphism and pain sensitivity in patients with a history of leg and back pain, diagnosed with LDH, who underwent lumbar discectomy.
Methods
A total of 270 patients were initially asked to participate in the study, but some refused mainly due to the long distance to clinical center for follow-up. Two hundred thirty-three patients were recruited for the study (clinical evaluation and preoperative visual analog scale [VAS] score measurement) at the Neurosurgery Department of the Medical University of Gdansk, Poland. Fifty-seven did not complete 12-month follow-up, mainly due to noshow, but also diabetes, death of a patient, and dementia. Finally, 176 patients of Caucasian origin (mean age ¼ 46.7 6 13.2 years, age range ¼ 20-80 years, 41.5% female) diagnosed with lumbar disc herniation who had been subjected to lumbar discectomy were enrolled. The main inclusion criterion was persistent back and leg pain resistant to conservative therapy for at least six months that was associated with lumbar disc herniation on computed tomography or magnetic resonance imaging scans. The surgery, that is, discectomy, was performed at one of the levels from L3 to S1, from the midline standard posterior approach with assistance of an intraoperative microscope, by one of four neurosurgeons.
In order to standardize the clinical indications for surgery, the following were considered the exclusion criteria: spine fracture history, spinal tumors, patients with serious osteoporosis disqualifying for surgery, fixed motor deficit, spinal stenosis, cauda equina syndrome, spine deformities, patients who had progression of symptoms and required immediate surgery, reoperation. The patients with long-term diabetes mellitus with polyneuropathy and those diagnosed with sensorimotor polyneuropathy on a different background were also excluded from the study due to the change in the threshold of pain sensitivity associated with the above diseases. Another exclusion criterion was the treatment with drugs prescribed for neuropathic pain, including antidepressants such as SNRI-duloxetine, venlafaxine, TLPD-amitriptyline, as well as gabapentinoids, for example, pregabalin and gabapentin, due to their potential influence on the assessment of pain severity. The patients with moderate to severe dementia (Mini-Mental State Exmaination < 19) were excluded from the study due to the possible difficulties with objective pain assessment.
The pain intensity was measured by means of the VAS (range 0-10), separately for lower back pain (VASBACK) and leg pain (VASLEG), self-completed by the study participants. The patients who enrolled in the study received a detailed questionnaire concerning the analgesic treatment before and after surgery. The questionnaire asked about the type, daily dose, and frequency of use of analgesics and/or physiotherapeutic treatment. The medical examination was performed at least 72 hours after discontinuation of both nonopioid and opioid analgesics to maximize the objectification of pain during clinical evaluation. All patients were evaluated twice: before the surgery and 12 months postoperation. The study protocol was approved by the local ethics committee, and each patient signed an informed consent form.
Frozen genomic DNA samples (20 ng/mL) were available from the previous study [10] . The SNP within SCN9A gene was evaluated using prevalidated allelic SCN9A Polymorphism and Chronic Pain Intensity discrimination TaqMan real-time polymerase chain reaction (PCR) assay (assay ID: C__29330435_10, Life Technologies, Carlsbad, CA, USA). PCR thermal profile consisted of initial denaturation at 95 C for two minutes and 40 cycles at 95 C for five seconds/60 C for 15 seconds; all reactions were run using GTXpress master mix (Life Technologies, USA). Fluorescence data were captured using 7500 FAST Real-Time PCR System (Applied Biosystems, Foster City, CA, USA.) after reaction termination.
The consistency of the genotype distribution with the Hardy-Weinberg equilibrium (HWE) was assessed using Fisher's exact test. VAS scores were checked for their concordance with normal distribution using the ShapiroWilk test, which showed strong deviation from normality (P < 0.0001). Therefore, the scores were subsequently compared between the genotype groups using the nonparametric Mann-Whitney test. P values of P < 0.05 were considered statistically significant.
Results
The mean value of VASBACK score among all study participants (6SD) was 6.7 6 2.7, and it significantly decreased at 12 months after the surgery (4.4 6 2.9, VASBACK change ¼ 2.3 6 2.9). Similarly, mean VASLEG values were significantly reduced by the surgical treatment (7.0 6 2.6 preoperative to 4.0 6 3.2 postoperative, mean change ¼ 3.0 6 3.6). The distribution of SCN9A rs6746030 genotypes was in concordance with Hardy-Weinberg equilibrium (P ¼ 0.20). The GG genotype was determined in 134 patients (76.1%), 37 subjects were heterozygotes (21.0%), and minor homozygous AA genotype was present in five patients (2.8%). Minor allele frequency (MAF ¼ 0.134) was similar to that obtained for the European population in the 1000 Genomes Project (MAF ¼ 0.126, http://www. 1000genomes.org). Because the AA homozygous genotype was rare among the study participants, A allele carriers (GA and AA genotypes) were pooled together for further analyses. A significantly higher preoperative back pain intensity was observed among rs6746030 A allele carriers when compared with GG homozygotes (7.5 6 2.4 vs 6.5 6 2.7, P ¼ 0.012). Similarly, A allele carriers were characterized by higher values of leg pain evaluated by visual scale prior to surgery (7.8 6 2.3 vs 6.8 6 2.6, P ¼ 0.013). Twelve months after surgery, VASBACK and VASLEG scores were reevaluated, and values were still higher in the A allele carrier group, but the difference was not significant. Improvement in pain reduction (change in VAS score) was similar in both groups. Results are presented in Table 1 .
Discussion
The pathophysiology of radicular pain is unclear. However, the role of neural compression with axonal dysfunction, ischemia, inflammation, and biochemical influences is postulated. Neuropathic pain, one of the LBP components, produces a large detrimental effect on quality of life, partly due to low treatment efficacy [11] . The understanding of physiological processes or genetic predispositions contributing to persistent LBP may help to identify high-risk patients and target interventions accordingly. An important role of voltage-gated sodium channels in many different pain states has been established in animal models and in humans [12] . Genetic and functional studies have revealed that voltage-gated sodium channel NaV1.7, preferentially expressed in peripheral somatic and visceral sensory neurons and sympathetic ganglion neurons, is a major contributor to pain signaling in humans [13] . The original concept that a nonsynonymous single nucleotide polymorphism (rs6746030: G > A) within the SCN9A sequence could influence NaV1.7 sodium channel function was formulated by Estacion et al. The authors identified arginine to tryptophan substitution in a conservative residue of the encoded protein during their studies on erythromelalgia, and subsequently demonstrated that minor A allele produced hyperexcitability [14] . Shortly afterward, Reimann et al. [9] revealed that the SCN9A polymorphism determines a difference in the voltage-dependent slow inactivation, with the minor A allele predicting an increase in NaV1.7 activity. The authors observed a significant association between SNP rs6746030 and pain score among osteoarthritis patients, sciatica pain, and phantom pain. In the same study, in a cohort of 179 Caucasian patients evaluated for pain using a seven-point score one year after lumbar discectomy, an association was marginally significant [9] . In the current study, we have observed an association of SCN9A rs6746030: G > A minor allele carrier status and higher pain intensity in patients with lumbar disc herniation. This association was significant prior to surgery, but not when evaluated 12 months postoperation. As a consequence of surgery, most patients experienced overall relief from pain symptoms, and mean VAS scores significantly decreased, regardless the patient's genotype. Hence, it is probable that the effect of the rs6746030 SNP is more pronounced in the case of higher intensity of pain stimuli, and markedly lower after surgical treatment. However, one cannot directly compare the results of different investigations, mainly due to differences in study design, but other factors, including ethnic differences, may also play a role.
The results of association studies on SCN9A polymorphism and pain that followed the original investigation were often contradictory. In the study, which recruited patients from three different cohorts, no genotypedependent differences in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores were observed in any of the cohorts. However, when all the study subjects were pooled together, significantly increased odds for multiple regional pain were observed in minor allele carriers [15] . Another population-based study negatively verified the association between SCN9A rs6746030 genotypes and chronic widespread pain [16] . It is worth mentioning that the latter study analyzed available data from four different populations and that methods of pain assessment and widespread pain classification criteria differed from one another. Pain analysis is problematic due to its subjective nature and difficulties in developing reliable scales characterizing pain. The method of pain assessment used in the current study (self-evaluation of VAS scores at one time point before and one time point after the operation) is one of its limitations, as choosing an appropriate and reliable method of pain assessment may have impact on study outcome. Moreover, quality of life and other functional parameters were not measured. However, it was presented by Landmark et al. [17] that a single evaluation of chronic pain intensity can replace multiple assessments with high sensitivity and specificity pain, as long as an appropriate method is applied.
In turn, a significant association between SCN9A rs6746030 minor allele carrier status and interstitial cystitis/bladder pain syndrome was reported, but the study was performed in a relatively small number of subjects, and the results must be viewed as preliminary [18] . As for non-Caucasian studies, it was reported that SCN9A rs6746030 may be associated with postoperative pain intensity (evaluated by numerical rating scale) in Chinese women who underwent gynecological laparoscopic surgery and refused postoperative patient-controlled analgesia [19] . The same authors investigated a set of tag SNPs within the SCN9A gene for their potential association with pain sensitivity. Both mechanical and heat pain sensitivity were measured in a large cohort of young women, and despite a low frequency in the studied population, rs6746030 was associated with some measures of mechanical pain, that is, sensitivity to pricking pain [20] . Different results from alternatively designed studies may suggest that the SNP is associated with the severity of pain rather than the presence or absence of pain [9, 16] .
As our previous paper [10] analyzed the association of COMT polymorphisms with pain intensity in the same group of LDH patients, we performed additional analyses to find whether SCN9A and COMT polymorphism are associated with each other and whether the currently reported associations between SCN9A polymorphism and pain intensity are independent of previously reported associations between COMT polymorphisms and pain intensity. The analyses showed that there was no association (P > 0.3, chi-square test) between rs6746030 SCN9A polymorphism and any of the four previously studied COMT polymorphisms (rs4680, rs6269, rs4633, rs4818) in our patients. This result could be expected as the SCN9A gene is located on chromosome 2 and the COMT gene on chromosome 22. Multivariate linear regression analysis showed that the associations of SCN9A rs6746030 allele A with higher preoperative lower back and leg pain intensity were independent of the associations with COMT polymorphisms as they remained significant (P < 0.03) when both SCN9A and COMT polymorphisms were included in the regression models.
Finally, our results suggest that SCN9A rs6746030 polymorphism may be associated with pain intensity in patients suffering from symptomatic disc herniation. This finding has limited clinical utility but supports the functional character of the investigated missense variant. Genetic polymorphism may be responsible in part for interpersonal variability in intensity of pain triggered by similar stimuli. However, further studies and meta-analyses will finally verify the significance of SCN9A rs6746030 polymorphism in pain sensitivity and intensity.
